BBIO BridgeBio Pharma Inc

Price (delayed)

$11.6

Market cap

$1.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.5

Enterprise value

$2.96B

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in ...

Highlights
BridgeBio Pharma's revenue has increased by 45% YoY and by 28% from the previous quarter
The gross profit has grown by 37% YoY and by 29% from the previous quarter
BBIO's net income is up by 15% since the previous quarter but it is down by 2.8% year-on-year
BBIO's equity has dropped by 121% year-on-year
BBIO's debt is up by 23% year-on-year

Key stats

What are the main financial stats of BBIO
Market
Shares outstanding
148.25M
Market cap
$1.72B
Enterprise value
$2.96B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
18.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.66
Earnings
Revenue
$90.67M
EBIT
-$442.54M
EBITDA
-$431.67M
Free cash flow
-$348.8M
Per share
EPS
-$3.5
Free cash flow per share
-$2.38
Book value per share
-$6.94
Revenue per share
$0.62
TBVPS
$5.67
Balance sheet
Total assets
$862.23M
Total liabilities
$1.88B
Debt
$1.71B
Equity
-$1.03B
Working capital
$630.12M
Liquidity
Debt to equity
-1.67
Current ratio
5.46
Quick ratio
5.23
Net debt/EBITDA
-2.88
Margins
EBITDA margin
-476.1%
Gross margin
94.4%
Net margin
-561.8%
Operating margin
-627.5%
Efficiency
Return on assets
-58.7%
Return on equity
N/A
Return on invested capital
-22.1%
Return on capital employed
-61.4%
Return on sales
-488.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
6.62%
1 week
3.66%
1 month
20.96%
1 year
-77.18%
YTD
-30.46%
QTD
27.75%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$90.67M
Gross profit
$85.62M
Operating income
-$568.97M
Net income
-$509.37M
Gross margin
94.4%
Net margin
-561.8%
BridgeBio Pharma's revenue has increased by 45% YoY and by 28% from the previous quarter
The gross profit has grown by 37% YoY and by 29% from the previous quarter
BBIO's net margin is up by 33% since the previous quarter and by 29% year-on-year
BBIO's operating margin is up by 24% QoQ and by 23% YoY

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
18.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.66
BBIO's EPS is up by 14% since the previous quarter and by 9% year-on-year
BBIO's equity has dropped by 121% year-on-year
The stock's price to sales (P/S) is 61% less than its last 4 quarters average of 47.7
BridgeBio Pharma's revenue has increased by 45% YoY and by 28% from the previous quarter

Efficiency

How efficient is BridgeBio Pharma business performance
BBIO's ROS is up by 36% since the previous quarter and by 32% year-on-year
The ROIC has grown by 33% YoY and by 18% from the previous quarter
The ROA has grown by 9% from the previous quarter but it has contracted by 9% YoY

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 54% smaller than its total liabilities
BridgeBio Pharma's quick ratio has decreased by 22% YoY and by 21% from the previous quarter
BBIO's total liabilities is up by 22% YoY
BBIO's equity has dropped by 121% year-on-year
BBIO's debt to equity is up by 45% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.